These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 19182242)
1. Oligodendrogliomas: molecular biology and treatment. Bromberg JE; van den Bent MJ Oncologist; 2009 Feb; 14(2):155-63. PubMed ID: 19182242 [TBL] [Abstract][Full Text] [Related]
2. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A; Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167 [TBL] [Abstract][Full Text] [Related]
3. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236 [TBL] [Abstract][Full Text] [Related]
4. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966 [TBL] [Abstract][Full Text] [Related]
5. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687 [TBL] [Abstract][Full Text] [Related]
6. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Walker C; Haylock B; Husband D; Joyce KA; Fildes D; Jenkinson MD; Smith T; Broome J; du Plessis DG; Warnke PC Neurology; 2006 Jun; 66(11):1661-7. PubMed ID: 16769937 [TBL] [Abstract][Full Text] [Related]
7. [Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice]. Fontaine D; Vandenbos F; Lebrun C; Paquis V; Frenay M Rev Neurol (Paris); 2008; 164(6-7):595-604. PubMed ID: 18565359 [TBL] [Abstract][Full Text] [Related]
8. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. Kros JM; Gorlia T; Kouwenhoven MC; Zheng PP; Collins VP; Figarella-Branger D; Giangaspero F; Giannini C; Mokhtari K; Mørk SJ; Paetau A; Reifenberger G; van den Bent MJ J Neuropathol Exp Neurol; 2007 Jun; 66(6):545-51. PubMed ID: 17549014 [TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Kouwenhoven MC; Gorlia T; Kros JM; Ibdaih A; Brandes AA; Bromberg JE; Mokhtari K; van Duinen SG; Teepen JL; Wesseling P; Vandenbos F; Grisold W; Sipos L; Mirimanoff R; Vecht CJ; Allgeier A; Lacombe D; van den Bent MJ Neuro Oncol; 2009 Dec; 11(6):737-46. PubMed ID: 19224764 [TBL] [Abstract][Full Text] [Related]
10. [The oligodendroglioma: the value of histologic and genetic diagnosis in predicting sensitivity to chemotherapy]. Kros JM Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1379-85. PubMed ID: 15997690 [TBL] [Abstract][Full Text] [Related]
11. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Lavon I; Zrihan D; Zelikovitch B; Fellig Y; Fuchs D; Soffer D; Siegal T Clin Cancer Res; 2007 Mar; 13(5):1429-37. PubMed ID: 17332285 [TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender. Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770 [TBL] [Abstract][Full Text] [Related]
13. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Jenkinson MD; du Plessis DG; Smith TS; Joyce KA; Warnke PC; Walker C Brain; 2006 Jul; 129(Pt 7):1884-91. PubMed ID: 16670176 [TBL] [Abstract][Full Text] [Related]
14. Molecular genetic markers as predictors of response to chemotherapy in gliomas. Idbaih A; Omuro A; Ducray F; Hoang-Xuan K Curr Opin Oncol; 2007 Nov; 19(6):606-11. PubMed ID: 17906460 [TBL] [Abstract][Full Text] [Related]
15. Novel genomic alterations and mechanisms associated with tumor progression in oligodendroglioma and mixed oligoastrocytoma. Blesa D; Mollejo M; Ruano Y; de Lope AR; Fiaño C; Ribalta T; García JF; Campos-Martín Y; Hernández-Moneo JL; Cigudosa JC; Meléndez B J Neuropathol Exp Neurol; 2009 Mar; 68(3):274-85. PubMed ID: 19225409 [TBL] [Abstract][Full Text] [Related]
16. Anaplastic oligodendroglioma and oligoastrocytoma. van den Bent MJ Neurol Clin; 2007 Nov; 25(4):1089-109, ix-x. PubMed ID: 17964027 [TBL] [Abstract][Full Text] [Related]
17. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Zlatescu MC; TehraniYazdi A; Sasaki H; Megyesi JF; Betensky RA; Louis DN; Cairncross JG Cancer Res; 2001 Sep; 61(18):6713-5. PubMed ID: 11559541 [TBL] [Abstract][Full Text] [Related]